Abstract
Background Compound mutations of TNNT2R141W/+ (encoding troponin T) and MYPNS1296T/+ (encoding myopalladin) are associated with familial left ventricle non-compaction cardiomyopathy (LVNC). However, it remains unclear in which would be the pathogenic mutation, the underlying mechanism, and the target therapy for LVNC.
Methods Knock-in C57BL/6J mice harboring mutations in orthologous genes in Tnnt2R154W or/and MypnS1291T and human cardiomyocytes derived from iPSC of healthy donors and LVNC patients (LVNC-hCM) were employed for disease modeling, omics analysis, mechanistic study, and drug development.
Results Using knock-in mice for disease modeling, it was clarified that the orthologous mutation in Tnnt2, but not in Mypn, led to cardiac hypertrabeculation, noncompaction, and heart failure. 3D protein structure modeling by Swiss-model found a loss of slat bridge between TNNT2(R141W) and E-257 in tropomyosin, contributing to the decreased cardiac contraction. Further mechanistic study discovered that troponin T (TNNT2) appears to function as an HDAC1 sponge in cardiomyocyte nuclei. The compromised association between nuclear TNNT2(R141W) and HDAC1 causes cardiac epigenetic perturbation and subsequentially leads to transcriptional dysregulation. The downregulation of cardiac muscular genes was concomitant with the impairment of cardiac contraction, which would be partially rescued by pan HDAC inhibitor. Besides, the upregulation of TGFβ-signaling molecules and EZH2 did contribute to cardiac growth defects, which were mitigated by TGFβR1 inhibitor (A83-01) and EZH2 inhibitor (GSK503), respectively. Simvastatin, a hit drug identified from the repurposed drug screening, can restore nuclear TNNT2(R141W)-HDAC1 association, thereby recovering cardiac epigenetic, translational profiles, growth and function in LVNC-hCM in vitro and cardiac function in LVNC mice harboring Tnnt2R154W in vivo. The cardiac function was significantly improved in the proband receiving 5 mg once daily for consecutive two years.
Conclusion Mutant TNNT2(R141W) diminished its nuclear HDAC1 sponge function in cardiomyocyte to induce LVNC pathogenesis through perturbating cardiac epigenetic and the gene expressions. Targeting to HDAC, TGFβ, EZH2 may rescue part of cardiac pathological signaling. Simvastatin can act as a chemical chaperone to comprehensively recover cardiac epigenetic via restoring nuclear TNNT2(R141W)-HDAC1 association.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ClinicalTrials.gov: NCT06632834
Funding Statement
All funding supported in this work was provided by National Science and Technology Council in Taiwan (NSTC), National Health Research Institutes (NHRI), and the Excellent Translational Medicine Research Projects of National Taiwan University College of Medicine and National Taiwan University Hospital (ETMRP). NSTC105-2320-B-002 -036 -MY3, NSTC106-2314-B-002-207, NSTC108-2320-B-002 -027 -MY3, NHRI-EX112-11141SI, ETMRP-106R39012 & -1105F025-02 to C.W.P. NSTC106-2314-B-002-207 & NSTC109-2314-B-002-140 to W.M.H. NSTC-105-2314-B-002 -109 -MY3, NSTC107-2319-B-001 -003, ETMRP-106R39012 and ETMRP-1105F025-02 to H.H.N.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of National Taiwan University Hospital gave ethical approval (201612099RINC & 201912067MINB) for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
17. Data availability
All data and materials used for supporting the findings of the current study are available from the corresponding authors upon reasonable request and with materials transfer agreements (MTAs) for animal models or human cells to any researcher in the aim of reproducing or extending the analysis.
